The updated recommendations apply to industry and, when finalized, will update previous guidance issued in 2016.
Twenty lots of Abbott's FreeStyle and FreeStyle Lite blood glucose test strips were recalled.
Six batches of GlucaGen HypoKit (glucagon [rDNA origin] for injection) were recalled due to the possibility of needle detachment, the FDA recently announced.
The SPOTCHEM II Basic PANEL-1 Reagent Test Strip and SPOTCHEM II Glucose Reagent Test Strip may report falsely low blood glucose levels.
The pump can be used with various components of diabetes therapy systems, including automated insulin dosing systems, continuous glucose monitors, and blood glucose meters.
The injection is approved to improve glucose control in patients ages three years and older with type 1 diabetes and in adult patients with type 2 diabetes.
The FDA on Sept. 10 released a strengthened warning on canagliflozin (Invokana, Invokamet) about increased risk of bone fractures and decreased bone mineral density.
The FDA recently approved the first hemoglobin A1c (HbA1c) test specifically labeled for diagnosing diabetes.
As an adjunct to diet and exercise, the drug was approved as monotherapy and for use in fixed-dose combinations with metformin or sitagliptin.
Aliskiren-containing medications are contraindicated with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with diabetes.